HOME >> BIOLOGY >> NEWS
Drug strategy makes cancer genes get lost in translation

ghly structured, "untranslated regions" at their so-called 5' end, the researchers explained. The lengthy region of weak mRNAs serves as an obstacle for the ribosomal machinery that does the translating, making it a challenge to determine where to begin, he added.

In contrast, strong mRNAs have only short 5' untranslated regions that allow for easier protein formation. The successful translation of weak mRNAs therefore depends more heavily on other protein factors, called initiation factors, to help the process along.

In the current study, the researchers sought to capitalize on the weakness of cancer-related mRNAs by disrupting the interaction between two protein initiation factors, eIF4E and eIF4G.

Assembly of the eIF4E/eIF4G complex is known to have a central role in controlling genes at the level of translation initiation. The complex is normally kept under wraps by still other proteins, the 4E-BPs, which compete with the initiation factors for binding and have tumor-suppressor activity.

The researchers screened thousands of available small molecules for their ability to interfere with the initiation proteins' interaction in a manner similar to the 4E-BPs. The most potent compound identified, 4EGI-1, binds one of the proteins, eIF4E, thereby disrupting the ability of the eIF4E/eIF4G complex to do its job. That interference, in turn, blocked the formation of proteins that require assistance from initiation factors.

"Surprisingly, this compound does not inhibit binding of [the tumor suppressor] 4E-BP1 to eIF4E and instead causes a significant apparent increase in the amount of this protein that is bound," the researchers reported.

Treatment of mammalian cancer cells with the compound had a similar effect on the translation of weak mRNAs to that seen in the initial in vitro tests, they show. What's more, the level of a classic housekeeping gene remained unaffected in treated cells, while expression of tw
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
25-Jan-2007


Page: 1 2 3

Related biology news :

1. New strategy for treating allergic disorders
2. Does EPA have an adequate strategy to oversee nanotechnologies?
3. High blood pressure medication strategy proves effective in Hispanic women
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Scientists identify new strategy for preventing acute and chronic brain disease
6. International risk research strategy and funding needed for nanotech safety
7. Study shows metabolic strategy of stressed cell
8. Trojan horse strategy defeats drug-resistant bacteria
9. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug strategy makes cancer genes get lost translation

(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
(Date:7/2/2015)... ... 02, 2015 , ... Sleepless nights will become obsolete as Luzi , ... Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will love ... use, while the integration of the Bluetooth speaker, alarm clock and ability to charge ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
Cached News: